Century Therapeutics to Showcase CNTY-813 Preclinical Data at Major Scientific Congresses
Century Therapeutics, Inc. (NASDAQ: IPSC), a pioneering biotechnology firm focused on developing induced pluripotent stem cell (iPSC)-derived therapies for autoimmune diseases and cancer, has announced a significant milestone in its research journey. The company revealed that its abstracts highlighting CNTY-813, an innovative islet replacement therapy for type 1 diabetes (T1D), have been accepted for oral presentations at two prestigious scientific congresses later this year.
1. Upcoming Presentations at EASD and CRC 2026
Century Therapeutics will present its groundbreaking research on CNTY-813 at the following events:
- 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD)
- Location: Milan, Italy
- Date: September 28 – October 2, 2026
- Presentation Title: CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC-Derived Islets for Off-the-Shelf Cell Therapies
- Presenter: Grant Welstead, PhD, Senior Vice President and Head of Research
- Session: OP 39 – Beta cells on demand: stem cells to beta cell therapy
- Date/Time: October 2, 2026, from 10:00 to 11:00 AM CEST
- Breakthrough T1D® Clinical & Research Congress 2026 (CRC 2026)
- Location: Philadelphia, Pennsylvania
- Date: October 9 – 11, 2026
- Presentation Title: CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC Beta Islets for Off-the-Shelf Cell Therapies
- Presenter: Leonardo Velazco-Cruz, PhD, Islet Process Science
- Session: 0300 - ORALS 01: Cell Therapy Science & Clinical
- Date/Time: October 9, 2026, from 3:50 to 4:50 PM EDT
Both presentations promise to provide insights into the promising capabilities of CNTY-813, aiming to revolutionize the treatment landscape for T1D.
2. CNTY-813: A Game-Changer in Type 1 Diabetes Therapy
CNTY-813 is designed to be a groundbreaking iPSC-derived islet replacement therapy engineered with Century’s proprietary Allo-Evasion™ 5.0 technology. This innovative approach addresses a critical hurdle in the treatment of T1D — the need for chronic systemic immunosuppression, which has hindered the success of previous cell therapy options.
Key Benefits of CNTY-813
- Robust Functionality: Preclinical data indicates that CNTY-813 exhibits a strong glucose-responsive function, crucial for effective diabetes management.
- Safety Profile: The therapy shows a favorable preclinical safety profile, which is essential for potential clinical applications.
- Scalability: The manufacturing process for CNTY-813 has demonstrated scalability and reproducibility, which could facilitate broader patient access.
- Immune Protection: The innovative Allo-Evasion™ technology provides immune protection under alloimmune pressure, potentially allowing for durable engraftment without the need for long-term immunosuppressive therapies.
Century Therapeutics aims to submit an Investigational New Drug (IND) application for CNTY-813 in the fourth quarter of 2026, marking a significant step towards clinical trials.
3. About Century Therapeutics
Founded with a mission to advance innovative therapies, Century Therapeutics is at the forefront of biotechnology, leveraging its iPSC cell foundry to develop therapies that have the potential to address serious medical conditions like autoimmune diseases and cancer. The company’s development of off-the-shelf cell therapies is designed to expand patient access and offer alternatives to existing treatments.
As Century Therapeutics prepares for these critical presentations, the scientific community and investors alike will be watching closely to gauge the potential impact of CNTY-813 on the future of type 1 diabetes treatment. The upcoming congresses represent not just an opportunity to share their findings, but also to engage with key stakeholders in the field of diabetes research and therapy development.
